“…To enable non-invasive, high-resolution monitoring of heart function, these nanoparticles can carry imaging agents like contrast agents for MRI, positron emission tomography (PET), or optical imaging using fluorescent dyes. Nanotheranostic platforms also allow for the direct delivery of therapeutic drugs to the injured cardiac tissues, allowing for targeted, localised treatment with minimal systemic adverse effects 14 , 15 . Potential therapeutic payloads encompass antioxidants, cardioprotective drugs, or compounds that target certain pathways associated with cardiotoxicity, including oxidative stress or apoptosis.…”